Lazard Asset Management
OPRX icon

Lazard Asset Management’s OptimizeRx OPRX Stock Holding History

Lazard Asset Management’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,549
Closed -$42K – 2488
2022
Q2 		$42K Buy
+1,549
New +$45.9K ﹤0.01% 1891

Other funds holding OPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Lazard Asset Management's OPRX Position: Q3 2022 in Review

Lazard Asset Management sold out of OptimizeRx (OPRX) in Q3 2022, closing a stake of 1,549 shares — an estimated $42K sold.

Lazard Asset Management first reported a position in OPRX in Q2 2022 and held it in 1 quarter. The position peaked at $42K in Q2 2022. 128 funds tracked by Wall St. Rank hold OPRX as of Q3 2022.

  • Lazard Asset Management reported no remaining OptimizeRx position as of Q3 2022 after selling out during the quarter.
  • Lazard Asset Management sold 1,549 OptimizeRx shares in Q3 2022, an estimated $42K.
  • Lazard Asset Management first reported a position in OptimizeRx in Q2 2022 and held it in 1 quarter.
  • Lazard Asset Management's OptimizeRx position peaked at $42K in Q2 2022.
  • 128 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2022.

Based on Lazard Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.